Recent Chronic Lymphocytic Leukemia News

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

(June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion,... Continue Reading


Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia

(March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the... Continue Reading


Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

(September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.... Continue Reading